ExxPharma Therapeutics LLC and Halo Pharmaceutical Inc. Join Hands to Develop Products using Twin Screw Extrusion Technology
FREMONT,CA: Halo Pharmaceutical Inc. and ExxPharma Therapeutics LLC recently announced their collaboration in order to develop drugs for customers of Halo and ExxPharma by leveraging ExxPharma's innovative drug delivery systems and twin screw extrusion technology. ExxPharma is expected to be in charge of the technical development whereas Halo will handle the general responsibility of drug manufacturing and quality control at Halo's high-tech GMP-compliant manufacturing facility located in Whippany, NJ.
Twin screw extrusion comprises of a highly versatile as well as controlled precision manufacturing process that uses small amount mixing in order to boost efficiency, quality while reducing cost. This technology although, finds itself new to the Pharma domain, has garnered widespread acceptance with hot melt extrusion (HME), that ExxPharma have used previously to better the bioavailability of inadequately soluble drug substances.
"Collaborating with Halo allows us to serve our clients more efficiently using fully-integrated, cost-effective complementary services which encompass formulation as well as process feasibility studies, Phase I to Phase III clinical development and commercial production," said Isaac Ghebre-Sellassie, President, ExxPharma. "Halo has a remarkable track record of developing clinical trial material as well as commercially viable drug products for U.S. as well as European markets. This collaboration allows us to concurrently transfer analytical and manufacturing technologies from a research and development environment at ExxPharma to a GMP compliant manufacturing facility."
"We are excited about this collaboration with ExxPharma and it provides an alternative technology to our customers," said Lee Karras, CEO, Halo Pharmaceutical Inc. "Moreover, Isaac is a preeminent scientist in this field and his guidance can be a tremendous asset for our customers who face challenges with bioavailability or if they wish to pursue abuse deterrent technologies which HME can potentially provide," Karras added.
By Debra Jensen, CIO, Charlotte Russe
By Phil Jordan, CIO, Telefonica
By Alberto Ruocco, CIO, American Electric Power
By Sven Gerjets, SVP-IT, DIRECTV
By Adrian Mebane, VP-Global Ethics & Compliance, The Hershey...
By Mike Fitton, Wireless Business Unit Director, Altera
By Jim Kaskade, VP and GM, Big Data & Analytics, CSC
By Graham Welch, Director-Cisco Security, Cisco
By Michael Watkins, Senior Product Director, Global Knowledge
By Nelson C. Vincent, EdD, VP for IT and CIO, University of...
By Sharon Gietl, VP-IT & CIO, The Doe Run Company
By Arnold Leap, CIO, 1-800-Flowers.com
By Gary Barlet, CIO, USPS OIG
By Mike Dieter, CTO, Transplace
By Bill Schimikowski, VP, Customer Experience, Fidelity...
By Kevin Kometer, CIO, CME Group
By John Landwehr, Public Sector CTO, Adobe
By Marc Probst, CIO & VP, Intermountain Healthcare
By Charles Koontz, President & CEO, GE Healthcare IT & Chief...
By Jeff Bauserman, VP-Information Systems & Technology,...